Wegovy 2.4 mg solution for injection in pre-filled pen

DRUG9 trials

Sponsors

Region Hovedstaden, Helse Bergen HF, Novo Nordisk A/S, Centre Hospitalier Universitaire D'Angers, Rigshospitalet

Conditions

Cannabis dependence (Cannabis Use Disorder or CUD)Cardiovascular diseaseCraniopharyngiomaDiabetes MellitusIdiopathic Intracranial HypertensionMetabolic control in antipsychotic-using patientsNon-alcoholic steatohepatitis (NASH)Obesity (BMI≥30kg/m2)

Phase 2

FIT-HF - Effect of weight loss on physical and cardiac performance in patients with heart failure and obesity

RecruitingCTIS2023-503753-35-01

Region HovedstadenObesity and Heart Failure with reduced Ejection Fracition

Start: 2024-03-20Target: 100Updated: 2025-08-22

A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder

Not yet recruitingCTIS2025-524163-21-00

Region HovedstadenCannabis dependence (Cannabis Use Disorder or CUD)

Target: 100Updated: 2026-03-30

Phase 3

The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

Active, not recruitingCTIS2023-506962-30-00

Novo Nordisk A/SNon-alcoholic steatohepatitis (NASH)

Start: 2021-03-29Target: 219Updated: 2025-11-11

An interventional, multi-center, randomized, double blinded, placebo controlled study to investigate semaglutide add-on treatment for metabolic control in antipsychotic-using patients (STABIL-NOR – study)

RecruitingCTIS2023-506109-20-00

Helse Bergen HFMetabolic control in antipsychotic-using patients

Start: 2024-10-19Target: 140Updated: 2024-12-19

Is the glucagon-like peptide-1 receptor agonist semaglutide able to alleviate mood in patients with major depressive disorder and overweight or obesity? Sema-Mood.

RecruitingCTIS2024-511734-13-04

Region HovedstadenObesity and overweight, Unipolar depression Overweight and obesity

Start: 2025-05-15Target: 120Updated: 2025-12-23

Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascular Disease: the SEMA-PLAT Study

Not yet recruitingCTIS2025-522486-29-01

Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco PasqualiCardiovascular disease, Diabetes Mellitus, Obesity (BMI≥30kg/m2) +1

Target: 212Updated: 2026-04-23

SEMAFORCRANIO : Multicenter, double-blind, parallel, randomized controlled trial of the efficacy of semaglutide in hypothalamic obesity secondary to craniopharyngioma in children aged 12 to 17 years

Not yet recruitingCTIS2024-511114-20-00

Centre Hospitalier Universitaire D'AngersCraniopharyngioma

Target: 50Updated: 2026-04-27

Phase 4

Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension

CompletedCTIS2024-517120-19-02

RigshospitaletIdiopathic Intracranial Hypertension

Start: 2022-09-02End: 2025-10-28Target: 50Updated: 2025-06-04

TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study)

Not yet recruitingCTIS2025-524819-37-00

Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarreobstructive sleep apnea

Target: 345Updated: 2026-03-30